Want to buy a stock at all time low?
On 1/5/2022 Barclays Boosted the Price Target for AVROBIO, Inc. (AVRO) from Overweight to Overweight and the price target from $6.00 to $22.00.
Now AVRO is $1.34. The next important resistance at $3.80.
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have...
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.
If...
Tickeron AI shows that a buy signal is indicated by this change in price, due to the trend repositioning higher. In 2 of 2 cases where AVRO's 50-day Moving Average crossed above its 200-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.
Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
AVRO 4H chart: BUY/HOLD 60% gains(NEW)
🔸 Summary and potential...
before we kick start the update. your upvotes/subs are appreciated.
Why get subbed to to me on Tradingview?
-15+ years real live trading experience
-TOP Author on TradingView
-professional chart break downs
-key levels
-no junk on my charts
-frequent updates
-covering FX/crypto/US stocks
-24/7 uptime so constant updates
So without further due. Keep it...
AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events.
However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and...
